cagrisema novo nordisk

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

CNBC on MSN · 2h

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

AOL · 1d

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk Stock Rises

Seeking Alpha · 8h

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO stock from hold to buy.

Investopedia on MSN · 12h

Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double

KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid "intensifying competition.

CNBC on MSN · 16h

Novo Nordisk's posts net profit beat as Wegovy sales jump 107% in fourth quarter

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth quarter came in at 28.

3hon MSN

Novo doubles down on next-gen weight loss therapy despite early setback

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

1hon MSN

Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

6hon MSN

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

NVO CLASS ACTION: BFA Law Alerts Novo Nordisk Investors of the Imminent March 25 Class Action Deadline

New York, New York-- (Newsfile Corp. - February 5, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

16h

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk Stock Rises

Related topics